Guifeng Liu
Songpingshan Road, Nanshan District
Shenzhen, 518057, China
Shenzhen, 518057, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC.
Journal: Theranostics
Published: January 10, 2021
A rare multiple primary sarcomatoid carcinoma (SCA) of small intestine harboring driver gene mutations: a case report and a literature review.
Journal: Translational cancer research
Published: September 03, 2020
Mutational Profile Evaluates Response and Survival to First-Line Chemotherapy in Lung Cancer.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: August 25, 2020
Disease progression and pseudoprogression following partial response with rare gingiva metastasis upon IBI308 (sintilimab) immunotherapy reflects the complexity of metastatic lung cancer: a case report.
Journal: Translational cancer research
Published: August 15, 2020
The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.
Journal: International journal of cancer
Published: August 06, 2020
The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility.
Journal: Translational lung cancer research
Published: July 18, 2020
ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC.
Journal: Frontiers in oncology
Published: March 22, 2020
Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population.
Journal: Scientific reports
Published: May 13, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026